ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,721.60
-1.06%
S&P ASX All Technology
3,063.30
-0.61%
Brent Oil
84.01
0.54%
US Dollar vs AUD
1.51071
-0.65%
Bitcoin
62,460.00
2.08%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Nektar Therapeutics (NKTR)

  7. Nektar Therapeutics (NKTR) News

NKTR

Nektar Therapeutics (NKTR)

Nektar Therapeutics
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NKTR
DateTimeSourceHeadlineSymbolCompany
10/05/202406:15PR Newswire (US)Nektar Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:NKTRNektar Therapeutics
03/05/202408:00PR Newswire (US)Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial MarketsNASDAQ:NKTRNektar Therapeutics
23/03/202405:00PR Newswire (US)Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceNASDAQ:NKTRNektar Therapeutics
06/03/202409:11Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NKTRNektar Therapeutics
06/03/202401:00PR Newswire (US)Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia AreataNASDAQ:NKTRNektar Therapeutics
05/03/202408:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NKTRNektar Therapeutics
05/03/202408:15PR Newswire (US)Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial ResultsNASDAQ:NKTRNektar Therapeutics
05/03/202400:40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NKTRNektar Therapeutics
05/03/202400:30PR Newswire (US)Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGXNASDAQ:NKTRNektar Therapeutics
28/02/202410:00PR Newswire (US)Nektar Management to Present at the TD Cowen 44th Annual Health Care ConferenceNASDAQ:NKTRNektar Therapeutics
27/02/202410:00PR Newswire (US)Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial MarketsNASDAQ:NKTRNektar Therapeutics
23/02/202412:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
23/02/202412:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
23/02/202412:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
21/02/202407:55Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NKTRNektar Therapeutics
21/02/202407:51Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NKTRNektar Therapeutics
21/02/202407:50Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NKTRNektar Therapeutics
17/02/202409:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NKTRNektar Therapeutics
15/02/202409:03Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NKTRNektar Therapeutics
15/02/202400:50Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NKTRNektar Therapeutics
11/01/202408:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NKTRNektar Therapeutics
04/01/202410:00PR Newswire (US)Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CANASDAQ:NKTRNektar Therapeutics
16/12/202310:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
16/12/202310:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
16/12/202310:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
16/12/202304:18Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NKTRNektar Therapeutics
12/12/202310:00PR Newswire (US)Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual MeetingNASDAQ:NKTRNektar Therapeutics
28/11/202308:55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NKTRNektar Therapeutics
21/11/202313:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
21/11/202313:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
 Showing the most relevant articles for your search:NASDAQ:NKTR

Your Recent History

NYSE
KO
Coca Cola
NASDAQ
AAPL
Apple
NASDAQ
NVDA
NVIDIA
NYSE
NKE
Nike
ASX
BHP
BHP
ASX
WES
Wesfarmers
NYSE
MRK
Merck
FTSE
UKX
FTSE 100
COIN
ETHUSD
Ethereum
CCOM
SILVER
SILVER
ASX
WOW
Woolworths
ASX
RIO
Rio Tinto
FX
AUDUSD
AUD vs US Dollar
PM
XAUUSD
Gold vs US Dollar
ASX
WDC
Westfield
NASDAQ
AMZN
Amazon.com
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved